Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex

Neurochemistry International

Volumn 57, Issue 8, 2010, Pages 985-989

  Lee, Jasinda H ^a,b   Agacinski, Grzegorz ^c   Williams, Jonathan H ^c   Wilcock, Gordon K ^c   Esiri, Margaret M ^c   Francis, Paul T ^d   Wong, Peter T H ^a,b   Chen, Christopher P ^a,b   Lai, Mitchell K P ^a,b,e  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Singapore General Hospital   (United Kingdom)

Author keywords

Alzheimer's disease; Cannabinoid CB1 receptors; Caudate; Cortex; Dementia; Hippocampus

Indexed keywords

CANNABINOID 1 RECEPTOR; NEUROTRANSMITTER;

AGED; ALZHEIMER DISEASE; ARTICLE; CAUDATE NUCLEUS; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL;

EID: 78649634580     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.10.010     Document Type: Article

References (46)

1. S.A. Areosa, F. Sherriff, and R. McShane Memantine for dementia Cochrane Database Syst. Rev. 2005 CD003154
2. B.S. Basavarajappa, R.A. Nixon, and O. Arancio Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration Mini Rev. Med. Chem. 9 2009 448 462
3. C. Benito, E. Núñez, R.M. Tolon, E.J. Carrier, A. Rabano, C.J. Hillard, and J. Romero Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J. Neurosci. 23 2003 11136 11141
4. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst. Rev. 2006 CD005593
5. H. Braak, and E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 82 1991 239 259
6. G.A. Cabral, E.S. Raborn, L. Griffin, J. Dennis, and F. Marciano-Cabral CB2 receptors in the brain: role in central immune function Br. J. Pharmacol. 153 2008 240 251
7. V.A. Campbell, and A. Gowran Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152 2007 655 662
8. J. Court, C. Martin-Ruiz, M. Piggott, D. Spurden, M. Griffiths, and E. Perry Nicotinic receptor abnormalities in Alzheimer's disease Biol. Psychiatry 49 2001 175 184
9. A. Degroot, C. Salhoff, R.J. Davis, and G.G. Nomikos Genetic deletion of CB1 receptors improves non-associative learning Behav. Brain Res. 162 2005 161 164
10. S.T. DeKosky, and J.M. Orgogozo Alzheimer disease: diagnosis, costs, and dimensions of treatment Alzheimer Dis. Assoc. Disord. 15 Suppl. 1 2001 S3 S7
11. Double, K.L., Reyes, S., Werry, E.L., Halliday, G.M., 2010. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol., doi:10.1016/j.pneurobio.2010.06.001.
12. G. Esposito, D. De Filippis, R. Carnuccio, A.A. Izzo, and T. Iuvone The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells J. Mol. Med. 84 2006 253 258
13. L.M. Eubanks, C.J. Rogers, A.E. Beuscher, G.F. Koob, A.J. Olson, T.J. Dickerson, and K.D. Janda A molecular link between the active component of marijuana and Alzheimer's disease pathology Mol. Pharm. 3 2006 773 777
14. D.D. Flynn, G. Ferrari-DiLeo, D.C. Mash, and A.I. Levey Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease J. Neurochem. 64 1995 1888 1891
15. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J. Psychiatr. Res. 12 1975 189 198
16. P.T. Francis Targeting cell death in dementia Alzheimer Dis. Assoc. Disord. 20 2006 S3 S7
17. P.T. Francis Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease Neurodegeneration 5 1996 461 465
18. H. Geerts, and G.T. Grossberg Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease J. Clin. Pharmacol. 46 2006 8S 16S
19. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
20. J.W. Huffman The search for selective ligands for the CB2 receptor Curr. Pharm. Des. 6 2000 1323 1337
21. F.A. Huppert, C. Brayne, C. Gill, E.S. Paykel, and L. Beardsall CAMCOG - a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample Br. J. Clin. Psychol. 34 1995 529 541
22. R.N. Kalaria, G.E. Maestre, R. Arizaga, R.P. Friedland, D. Galasko, K. Hall, J.A. Luchsinger, A. Ogunniyi, E.K. Perry, F. Potocnik, M. Prince, R. Stewart, A. Wimo, Z.X. Zhang, and P. Antuono Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors Lancet Neurol. 7 2008 812 826
23. Y. Kawamura, M. Fukaya, T. Maejima, T. Yoshida, E. Miura, M. Watanabe, T. Ohno-Shosaku, and M. Kano The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum J. Neurosci. 26 2006 2991 3001
24. A.C. Kreitzer, and W.G. Regehr Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells Neuron 29 2001 717 727
25. 2 binding in the cortex Neurology 57 2001 805 811
26. M. López De Jesús, J. Sallés, J.J. Meana, and L.F. Callado Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates Neuroscience 140 2006 635 643
27. G.A. McPherson Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC J. Pharmacol. Methods 14 1985 213 228
28. S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, L.M. Brownlee, F.S. Vogel, J.P. Hughes, G. van Belle, and L. Berg The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486
29. A. Nordberg, I. Alafuzoff, and B. Winblad Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia J. Neurosci. Res. 31 1992 103 111
30. T. Ohno-Shosaku, H. Tsubokawa, I. Mizushima, N. Yoneda, A. Zimmer, and M. Kano Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses J. Neurosci. 22 2002 3864 3872
31. J.W. Olney, D.F. Wozniak, and N.B. Farber Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies Arch. Neurol. 54 1997 1234 1240
32. B.G. Ramírez, C. Blázquez, T. Gómez del Pulgar, M. Guzmán, and M.L. de Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J. Neurosci. 25 2005 1904 1913
33. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Neliat, D. Caput, P. Ferrara, P. Soubrié, J.C. Brelire, and G. Le Fur SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244
34. M. Roth, E. Tym, C.Q. Mountjoy, F.A. Huppert, H. Hendrie, S. Verma, and R. Goddard CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia Br. J. Psychiatry 149 1986 698 709
35. D.J. Selkoe, and M.B. Podlisny Deciphering the genetic basis of Alzheimer's disease Annu. Rev. Genomics Hum. Genet. 3 2002 67 99
36. J.M. Sullivan Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids Learn. Mem. 7 2000 132 139
37. M.G. Tan, W.T. Chua, M.M. Esiri, A.D. Smith, H.V. Vinters, and M.K. Lai Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease J. Neurosci. Res. 88 2010 1157 1169
38. S.J. Thomas, and G.T. Grossberg Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias Clin. Interv. Aging 4 2009 367 377
39. S.W. Tsang, J. Pomakian, G.A. Marshall, H.V. Vinters, J.L. Cummings, C.P. Chen, P.T. Wong, and M.K. Lai Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease Neurobiol. Aging 28 2007 1381 1387
40. K. Tsou, S. Brown, M.C. Sanudo-Pena, K. Mackie, and J.M. Walker Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system Neuroscience 83 1998 393 411
41. T.M. Westlake, A.C. Howlett, T.I. Bonner, L.A. Matsuda, and M. Herkenham Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains Neuroscience 63 1994 637 652
42. P.J. Whitehouse, D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle, and M.R. Delon Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain Science 215 1982 1237 1239
43. G.K. Wilcock, M.M. Esiri, D.M. Bowen, and C.C. Smith The nucleus basalis in Alzheimer's disease: cell counts and cortical biochemistry Neuropathol. Appl. Neurobiol. 9 1983 175 179
44. R.I. Wilson, and R.A. Nicoll Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Nature 410 2001 588 592
45. A. Wimo, L. Jonsson, and B. Winblad An estimate of the worldwide prevalence and direct costs of dementia in 2003 Dement. Geriatr. Cogn. Disord. 21 2006 175 181
46. A. Wimo, L. Jonsson, and B. Winblad An estimate of the worldwide prevalence and direct costs of dementia in 2003 Dement. Geriatr. Cogn. Disord. 21 2006 175 181